Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
CDC backs wide use of Merck's Zostavax
TODAY'S SPOTLIGHT... CDC backs wide use of Merck's Zostavax
The Centers for Disease Control and Prevention is giving a boost to Merck's Zostavax vaccine. The public health agency is recommending that all adults 60 years and older should get the herpes zoster shot to prevent shingles, a painful and sometimes long-lasting disease. Complications of shingles, such a pneumonia and blindness, are more common among older folks. The CDC's advice comes after a long peer-review process, and its official stamp could prompt more doctors to give the vaccine--and, importantly, more private insurance companies to cover it. Release | Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
